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dexamethasone in ataxia-telangiectasia
ABSTRACT
Objective: Ataxia-telangiectasia (AT) is a rare, devastating neurodegenerative disease presenting
with early-onset ataxia, oculocutaneous telangiectasia, immunodeficiency, radiosensitivity, and
proneness to cancer. In a previous phase 2 study, we showed that 6 monthly infusions of autol-
ogous erythrocytes loaded with dexamethasone (EryDex; EryDel, Urbino, Italy) were effective in
improving neurologic impairment in young patients with AT. The present article reports the results
of the extension of this study for an additional 24-month period.
Methods: After the end of the first trial, 4 patients continued to be treated with monthly EryDex
infusions for an additional 24 months, and their clinical outcome was compared with that of 7
age-matched patients who stopped the treatment after the first 6 infusions. The protocol
included serial assessment of ataxia (by International Cooperative Ataxia Rating Scale) and adap-
tive behavior (by Vineland Adaptive Behavior Scales) and clinical and laboratory tests revealing
treatment- and steroid-dependent adverse effects, if present.
Results: Patients in the extended study experienced a continuous neurologic improvement with
respect to their pretreatment status, whereas controls showed a progressive neurologic deterio-
ration (according to the natural history of the disease) after the discontinuation of the treatment.
The delivery systemwe adopted proved to be safe and well-tolerated, and none of the side effects
usually associated with the chronic administration of corticosteroids were observed during the
entire trial.
Conclusions: These promising preliminary results call for a large-scale controlled study on pro-
tracted treatment of patients with AT with dexamethasone-loaded erythrocytes. Neurol
Neuroimmunol Neuroinflamm 2015;2:e98; doi: 10.1212/NXI.0000000000000098
GLOSSARY
AT5 ataxia-telangiectasia; ATM5 ataxia telangiectasia mutated; DSP5 dexamethasone phosphate; ICARS5 International
Cooperative Ataxia Rating Scale; VABS 5 Vineland Adaptive Behavior Scales.
Ataxia-telangiectasia (AT) is a rare genetic disease1,2 caused by mutations in the ataxia telangiec-
tasia mutated (ATM) gene, which results in a multisystemic disorder presenting with early-onset
ataxia, oculocutaneous teleangiectasias, progressive supranuclear ophthalmoplegia, immunodefi-
ciency, recurrent sinopulmonary infections, radiosensitivity, and proneness to cancer. In the classic
form, patients are wheelchair-dependent by the age of 10 years,1 and their life expectancy is
approximately 25 years.1,2 No effective disease-modifying therapy is presently available.
Observational studies have suggested that betamethasone may be effective in improving neu-
rologic functions in patients with AT.3,4 A controlled short-term trial confirmed the efficacy of
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oral betamethasone (0.1 mg/kg),5 but cortico-
steroid side effects were quickly observed. To
overcome these side effects and explore the
effects of a more protracted treatment on neu-
rologic outcome, we recently performed a
single-arm, open-label, 6-month extended
phase 2 trial in which the enrolled patients
received a monthly treatment of 50 mL of
autologous erythrocytes loaded with 2 vials
of 250 mg of dexamethasone phosphate
(DSP) by EryDex (EryDel, Urbino, Italy) pro-
cedure.6 Similarly to betamethasone, dexa-
methasone has a high anti-inflammatory
potency and lacks mineralcorticoid activity.
DSP is converted to dexamethasone by eryth-
rocytes’ phosphatases and released into the
bloodstream for about 20–30 days.7
After 6 infusions, patients experienced a
clinical improvement of about 5 points on
the International Cooperative Ataxia Rating
Scale (ICARS)8 and a significant improvement
in adaptive behavior, assessed by Vineland
Adaptive Behavior Scales (VABS),9 without
the occurrence of steroid-dependent adverse
events. The improvement was more relevant
in patients presenting with less severe neuro-
logic impairment and was affected by the effi-
ciency of the DSP loading procedure into
erythrocytes.6 We report the results of the
extension of this preliminary study for an addi-
tional 24-month period.
METHODS At the end of the first 6-month trial,6 4 male
patients (mean age 10.6 years; SD 2.8 years; range 8.7–14.2
years) requested and were authorized by the Ethic Committee to
continue EryDex treatment. So far they have been treated monthly
for an additional 24-month period. The ICARS and VABS scores
of the patients in the extended study before the beginning of the
treatment and after 6 and 24 EryDex infusions were compared with
those of the 7 patients with AT (2 male, 5 female; mean age 11.8
years; SD 3.5 years; range 8.2–19.2 years) who stopped the
treatment after the sixth infusion, as originally planned by the
study design.6 In accordance with a drug compassionate use
clause, the selection of the continuers was based on the parents’
decision (i.e., no external inclusion criterion could be applied), and
the controls were selected among discontinuers by trying to best
match the clinical characteristics of the continuers (table). During
the extension study, the loading procedure was further optimized
by obtaining an encapsulated DSP of 9.46 0.8 mg/bag (vs 6.76
6.9 in the previous study6) with the same dose of the medicament.
The assessment also included clinical and laboratory tests aimed at
detecting treatment- and steroid-dependent adverse effects.
Standard protocol approvals, registrations, and patient
consents. The extension was authorized by the Ethic Com-
mittee. Current Controlled Trial registration 2010-022315-
19SpA.
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RESULTS The table summarizes the clinical
response to the treatment at the end of the first 6
months (11 patients) and after 24 further months
in continuers (4 male patients) and discontinuers (7
patients; 2 male, 5 female). The mean DSP incorpo-
ration during both the original and extended trials is
also shown. At the end of the first 6-month trial,
ICARS and VABS scores of continuers and
discontinuers were ICARS 52.2 6 7.1 vs 43 6 2.9
and VABS 6 6 2.3 vs 8.2 6 0.6, respectively.
After 30 months, the patients in the extended study
experienced an improvement in ICARS score of 10.7
points (SD 6.75; range 2–17) with respect to the score
obtained at basal clinical evaluation. Conversely, the
ICARS score of the 7 patients who discontinued the
treatment worsened by 6.7 points (SD 6.5; range
13–16) (Mann-Whitney U 5 1.00; z 5 2.45; p 5
0.013803). Moreover, all continuers and only 1 of 7
discontinuers improved their ICARS score (Fisher exact
test, p 5 0.0152). Correspondingly, VABS average age
improved by 2.10 years (SD 2.4 years; range 9 months–
6.1 years) and by 0.9 years (SD 1 year; range 21.6 to
11.10 years) in continuers and discontinuers,
respectively (Mann-Whitney U 5 5.50; z 5 1.60;
p 5 0.10). Moreover, ICARS scores at the end of the
first 6-month trial and after 30 months improved by 8.2
points (SD 5.8; range 2–17) in the continuers and wors-
ened by 17.8 points (SD 6.9, range 24–26) in the
discontinuers (Mann-Whitney U 5 0.00; z 5 2.64;
p 5 0.008). Ataxia improved in 4 of 4 continuers and
in 1 of 7 discontinuers (Fisher exact test, p 5 0.015)
(figure). Concomitant variations in VABS among con-
tinuers and discontinuers were 2.6 years (SD 2.3 years;
range 0.5–4.9 years) and 21.7 years (SD 11 months;
range 24 months 12.9 years), respectively (Mann-
Whitney U 5 0.00; z 5 2.64; p 5 0.008).
No steroid-dependent adverse reactions were
observed during the entire treatment period. Standard
laboratory tests, physical examination, vital signs, and
ECG were all normal. Additional laboratory parame-
ters such as cholesterol (total, high-density lipoprotein,
and low-density lipoprotein), glycosylated hemoglobin
(HbA1c), and blood and urinary cortisol were all
within the normal range. CD41 lymphocyte count
remained stable during the treatment period but below
the normal range for 3 of the 4 patients. Blood
a-fetoprotein levels increased in all patients, regardless
of the treatment they underwent.
DISCUSSION Long-term corticosteroid administra-
tion is effective in slowing the progression of
Duchennemuscular dystrophy.10We recently reported
a statistically significant improvement in ataxic symp-
toms with DSP-loaded red cells in a cohort of young
patients with AT.6 Although this new treatment did
not have the usual side effects of chronic steroid
treatment, it was apparently less effective then oral
betamethasone treatment, which resulted in a
median improvement of 13 points on the ICARS
after a month of therapy.5 Present data are more
encouraging, showing that after 30 months of
treatment the patients experienced an improvement
of 10.7 points in mean ICARS score and 3 years in
VABS average age with respect to their basal condition.
Conversely, the ICARS score of the discontinuers at 30
months had worsened by 6.7 points and the VABS
average age had improved just 0.9 years. The gap of
26 ICARS points between continuers and
discontinuers at 30 months with respect to the score
obtained by the 2 groups after the first 6 months of
treatment is an important finding.
Albeit preliminary, the present results are impor-
tant: 2.5 years is a time span long enough to disclose
the progressive neurologic impairment that character-
izes the natural clinical history of AT.1,2 The fact that
the discontinuers experienced a decline of their neuro-
logic conditions once steroids were interrupted would
suggest a symptomatic effect of the treatment rather
than a plastic change involving the basic pathogenetic
Figure Neurologic impairment variation and duration of the treatment in
patients with ataxia-telangiectasia
The trend of International Cooperative Ataxia Rating Scale (ICARS) score variations (with
SD) in 4 patients with ataxia-telangiectasia who were treated for 30 months with monthly
infusions of autologous dexamethasone phosphate–loaded erythrocytes compared with
the ICARS scores of 7 patients who discontinued the treatment after the first 6 monthly
infusions. 0 (baseline), 7 (after the first 6 infusions), and 30 (after 30 months) represent the
scheduled time points for the subsequent assessments. In continuers, 30 is also the total
number of infusions before the last evaluation. In red is the common trial (0–7) for all 11
patients, in blue are the ICARS score variations in 4 continuers (0–30; 7–30), and in green
are the ICARS score variations in 7 discontinuers (0–30; 7–30). The increase of the score
reflects the worsening of ataxia.
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mechanism of the disease. Otherwise, the persistent
clinical improvement we observed so far in the contin-
uers conflicts with this hypothesis.
Several methodologic limitations (lack of blinding and
placebo in the treatment assignation, small size of the
sample, lack of external clinical criteria for patient enroll-
ment) affect our study, which was based on an empiric
post hoc observation. The lack of AT-dedicated rating
scales is a further intrinsic methodologic limitation. Nev-
ertheless, in the face of such a dramatic, untreatable dis-
ease, any clinical observation suggesting a potential
treatment deserves to be considered.
Whatever the biological effect of steroids in AT,
present data support the view that a protracted treat-
ment may delay and perhaps bias the natural course of
the disease. Moreover, the delivery system we adopted
was confirmed to be safe and well-tolerated, since
after this extended period of time no side effects could
be detected. A large-scale controlled study on pro-
tracted steroid treatment by DSP loaded into erythro-
cytes in patients with AT is mandatory in order to
verify these preliminary data.
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